We are shaping the future of companion diagnostics with innovative technologies. With our broad range of skills and resources, we create tailored partnership for your diagnostic needs – from complementary diagnostics for personalized medicine to solutions for individually tailored therapies and the development, production and validation of tailor-made assays.
In all Western societies, demographic development with an aging population and a decreasing birth rate in most industrialized countries calls for new approaches in healthcare. Steeply rising healthcare costs – not only in absolute numbers, but even in terms of percentage of GDP – clearly need a counterbalance in order to let healthcare remain affordable. A paradigm shift from “payment for procedure” towards “payment by performance” is clearly underway.
This is all the more necessary as such performance turns out to be a highly individual matter. Depending on the type of illness, half or more of all therapy efforts and spending may well be wasted because individual patients don’t respond to the respective therapy or even develop adverse effects calling for additional measures. The ability to correctly predict the outcome of a therapy is critical to each individual patient’s well-being, and to the overall affordability of the healthcare system.
Our diagnostic tests are applicable for disease management, earlier diagnosis, better patient selection and therapeutic drug monitoring. With the new RIDA®PRECISION real-time PCR products, the R-Biopharm AG product portfolio was extended by innovative test systems in the product lines pharmacogenetics and human genetics.
